This MedLibrary.org supplementary page on Ipratropium bromide is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Ipratropium
|
|
| Systematic (IUPAC) name | |
| [8-methyl-8-(1-methylethyl)- 8-azoniabicyclo[3.2.1] oct-3-yl] 3-hydroxy-2-phenyl-propanoate | |
| Identifiers | |
| CAS number | |
| ATC code | R01 R03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C20H30NO3 |
| Mol. mass | 332.457 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 0 to 9% in vitro |
| Metabolism | Hepatic |
| Half life | 2 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
B(US) |
| Legal status | |
| Routes | Inhalation |
Ipratropium (as ipratropium bromide, trade name Atrovent) is an anticholinergic drug.
Contents |
Uses
It is administered by inhalation for the treatment of obstructive lung diseases.
Ipratropium is also combined with albuterol (salbutamol) (trade names Combivent and Duoneb) for the management of chronic obstructive pulmonary disease (COPD) and asthma.
Ipratropium is also combined with fenoterol (trade names Duovent and Berodual N) for the management of asthma.
Pharmacology
It acts by blocking muscarinic receptors in the lung, inhibiting bronchoconstriction and mucus secretion. It is a non-selective muscarinic antagonist, and does not diffuse into the blood, which prevents systemic side effects. Ipratropium is a derivative of atropine[1] but is a quaternary amine and therefore does not cross the blood-brain barrier, which prevents central side effects (anticholinergic syndrome). Ipratropium is considered a short-acting bronchodilator.[2][3]
Side effects
If ipratropium is inhaled, side effects resembling other anticholinergics are minimal. However, dry mouth and sedation have been reported.
Sources
- Brenner, G. M. (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6
- Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4
- Boehringer Ingelheim
Footnotes
- ^ Yamatake Y, Sasagawa S, Yanaura S, Okamiya Y (1977). "[Antiallergic asthma effect of ipratropium bromide (Sch 1000) in dogs (author's transl)]" (in Japanese). Nippon Yakurigaku Zasshi 73 (7): 785–91. PMID 145994.
- ^ Kerstjens HA, Bantje TA, Luursema PB, et al. (2007). "Effects of short-acting bronchodilators added to maintenance tiotropium therapy". Chest 132 (5): 1493–9. doi:. PMID 17890476.
- ^ Knott L (November 20, 2007). "Antimuscarinic Bronchodilators". PatientUK. EMIS. Retrieved on 2008-06-16.
|
||||||||||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 5 October 2008, at 16:16.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Ipratropium bromide".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.